

# PRESS RELEASE

Lyon, June 14<sup>th</sup>, 2022



**ADOCIA**

innovative medicine  
for everyone, everywhere

## Number of shares and voting rights of ADOCIA as of May 31<sup>st</sup>, 2022

6pm CEST - Pursuant to the provisions of article L. 233-8 II of the French « Code de Commerce » and article 223-16 of the French stock-market authorities (*Autorité des Marchés Financiers*, or “AMF”) charter ADOCIA SA, a French *société anonyme* (corporation), 115, avenue Lacassagne, 69003 Lyon, (Euronext Paris: FR0011184241 – ADOC) a clinical stage biopharmaceutical company focused on treatment of diabetes, obesity and metabolic diseases with innovative formulations of approved proteins, releases its total number of outstanding shares as well as its voting rights as of May 31<sup>st</sup>, 2022.

Month	Date	Total number of outstanding shares	Total number of theoretical voting rights (1)	Total number of exercisable voting rights (2)
May	05/31/2022	8,060,362*	10,853,518	10,827,484

\*including 207,848 new shares resulting from the conversion of 860,000 convertible bonds into shares (OC 1023) issued by the Company on October 26, 2021, the main characteristics of which are described in its press release of the same day.

(1) The total number of theoretical voting rights (or “gross” voting rights) is used as the basis for calculating the crossing of shareholding thresholds. In accordance with Article 223-11 of the AMF General Regulation, this number is calculated on the basis of all shares to which voting rights are attached, including shares whose voting rights have been suspended.

(2) The total number of exercisable voting rights (or “net” voting rights) is calculated without taking into account the shares with suspended voting rights, in this case, shares held by the Company in the context of a liquidity agreement.

## About Adocia

[Adocia](#) is a biotechnology company specializing in the discovery and development of therapeutic solutions in the field of metabolic diseases, primarily diabetes and obesity. The company has a broad portfolio of drug candidates based on three proprietary technology platforms:

1) The BioChaperone® technology for the development of new generation insulins and products combining insulins with other classes of hormones; 2) An oral peptide delivery technology; 3) An immunoprotective biomaterial for cell transplantation with a first application in pancreatic cells transplantation for patients with "brittle" diabetes.

Adocia holds more than 25 patent families and was ranked 4<sup>th</sup> and 7<sup>th</sup> in the French National Institute of Industrial Property (INPI) ranking of SMEs on the number of patents filed, in 2019 and 2020 respectively.

Based in Lyon, the company has approximately 125 employees. Adocia is listed on the Euronext™ Paris market (Euronext: ADOC; ISIN: FR0011184241).

## Contact

### Adocia

**Gérard Soula**

CEO

[contactinvestisseurs@adocia.com](mailto:contactinvestisseurs@adocia.com)

Tel : +33 4 72 610 610

[www.adocia.com](http://www.adocia.com)

### Ulysse Communication

**Adocia Press and Investors Relations**

**Pierre-Louis Germain**

[plgermain@ulyse-communication.com](mailto:plgermain@ulyse-communication.com) / + 33 (0)6 64 79 97 51

**Margaux Puech Pays d'Alissac**

[mpuech@ulyse-communication.com](mailto:mpuech@ulyse-communication.com) / +33 (0)7 86 16 01 09

**Bruno Arabian**

[barabian@ulyse-communication.com](mailto:barabian@ulyse-communication.com) / +33 (0)6 87 88 47 26



European **Rising Tech**  
LABEL



**ADOCIA**

innovative medicine  
for everyone, everywhere



## Disclaimer

This press release contains certain forward-looking statements concerning Adocia and its business. Such forward-looking statements are based on assumptions that Adocia considers as being reasonable. However, there can be no guarantee that the estimates contained in such forward-looking statements will be achieved, as such estimates are subject to numerous risks including those which are set forth in the "Risk Factors" section of the universal registration document that was filed with the French Autorité des marchés financiers on April 21, 2022 (a copy of which is available at [www.adocia.com](http://www.adocia.com)), in particular uncertainties that are linked to research and development, future clinical data, analyses, and the evolution of the economic

context, the financial markets and the markets in which Adocia operates.

The forward-looking statements contained in this press release are also subject to risks not yet known to Adocia or not considered as material by Adocia as of this day. The occurrence of all or part of such risks could cause that actual results, financial conditions, performances, or achievements of Adocia be materially different from those mentioned in the forward-looking statements.

This press release and the information contained herein do not constitute an offer to sell or the solicitation of an offer to buy Adocia's shares in any jurisdiction.